… effects of ALN-AGT six months after single-dose administration. … of ALN-AGT to hypertensive
patients was generally well tolerated and resulted in profound reductions in serum AGT and …

… ALN-AGT, a subcutaneous investigational RNA interference (RNAi) therapeutic targeting
hepatic AGT … to assess the safety and tolerability of ALN-AGT, we conducted a multicenter study …

… – Severe and serious AE of prostate cancer reported in 1 patient who received 200 mg
ALN-… effect of ALN-AGT01 and potential durability of effect in lowering AGT beyond 3 months …

… The good news is that ALN-VSP02 is well-tolerated and has an antitumor activity. … protein
expressions of AGT in the liver were remarkably reduced and the blood levels of AGT and Ang …

… RNA interference technology, using synthetic structurally well-defined short double-stranded
RNA (small interfering RNA [… ALN-HSD is currently under evaluation in Phase I trials for this …

… RNA translation and small interfering RNA (siRNA) that function via the RNA interference …
vehicle or AGT small interfering RNA (siRNA) during the final 3 wk (n=7 per group). Middle, …

… RNA interference (RNAi), target degradation by RNase H-mediated cleavage, splicing
modulation, noncoding RNA … Initially, an intravenously administered LNP-formulated siRNA (ALN-…

… AGT-RVR had no impact on valsartan-induced AGT reduction. Post-AGR-RVR, a second
AGT… In summary, AGT-RVR is a highly selective tool for AGT and BP restoration in SHR. These …

… Second, it is unclear whether oligonucleotides that function via the RNA interference (RNAi)…
AGT siRNA [ALN-AGT RNAi] [30]. Briefly, patients receiving the investigational ALN-AGT …

… of ALN-GO1, an investigational RNA interference (RNAi) … Subcutaneous administration of
ALN-GO1 resulted in potent, … on PH1 and AGT deficiency, the robust nonclinical data with ALN-…